[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"steroid-resistant-pemphigus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:steroid-resistant-pemphigus":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100569628","phase-3-ono-4059-study-in-patients-with-steroid-resistant-pemphigus-100569628",false,"NCT06696716","ONO-4059 Study in Patients With Steroid-resistant Pemphigus","ONO-4059-10:Multicenter, Placebo-controlled, Randomized, Double-blind, Phase 3 Study in Patients With Steroid-resistant Pemphigus (BRILLIANT Study)","Inclusion Criteria:\n\n* Patients with a diagnosis of pemphigus\n* Patients with a re-increase in the pemphigus disease area index (PDAI) score before oral corticosteroid tapering to 10mg\u002Fday of prednisolone (PSL) equivalent\n\nExclusion Criteria:\n\n* Patients with an active infection\n* Patients with malignancy\n* Patients with past history of serious allergy or anaphylaxis","ALL","20 Years",{"count":19,"type":20},34,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","ONO-4059-10:Multicenter, placebo-controlled, randomized, double-blind, Phase 3 study in patients with steroid-resistant pemphigus",[26,27],"Pemphigus","Steroid-resistant Pemphigus","RECRUITING","2026-01-05",{"date":31,"type":32},"2026-01-07","ACTUAL",{"date":34,"type":32},"2022-08-15",{"date":36,"type":20},"2029-03-31",{"name":38,"class":39},"Ono Pharmaceutical Co., Ltd.","INDUSTRY",25]